Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 5:22 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 42% (105 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.22 | 1.52 | 9.99 |
Current Quarter Estimate | -0.21 | -2.04 | 61.00 |
Year Ago Quarter Estimate | -0.51 | -0.59 | 54.84 |
Next Quarter Estimate | -0.25 | -2.00 | 63.00 |
Next Year Estimate | -0.94 | 6.92 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -11.76 | 15.10 | 15.67 |
Next Year | 17.54 | 16.30 | 11.34 |
Last 5 Years | NA | 7.00 | 8.10 |
Next 5 Years | 2.50 | 24.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 3.17 | 1.58 |
Price/Cash Flow (MRFY) | NA | 8.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -226.46% | 6.02% |
Return on Equity (TTM) | -69.04% | 7.75% |
Debt to Equity (MRQ) | NA | 2.23 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.